Processa Seeks 900% Share Increase, Reverse Split to Bolster Capital

TL;DR

**PCSA is gearing up for massive dilution and a reverse split; existing shareholders should brace for impact.**

AI Summary

Processa Pharmaceuticals, Inc. (PCSA) is seeking stockholder approval for several critical proposals at a Special Meeting on September 2, 2025. The company proposes to increase its authorized common stock from 100,000,000 shares to 1,000,000,000 shares, a 900% increase, to provide flexibility for future capital raises and strategic transactions. Concurrently, PCSA plans a reverse stock split at a ratio between 1-for-2 and 1-for-50, at the Board's discretion, to potentially boost its stock price and maintain listing compliance. The company also seeks to amend its 2019 Omnibus Incentive Plan to increase shares available for issuance, subject to the authorized share increase. These actions are primarily aimed at improving the company's financial flexibility and market position, though they carry risks of dilution and potential negative market perception. The Board of Directors unanimously recommends a 'For' vote on all proposals.

Why It Matters

This DEF 14A filing reveals Processa Pharmaceuticals' urgent need to address its capital structure and potentially its stock price. The proposed 900% increase in authorized shares, from 100,000,000 to 1,000,000,000, signals an intent for significant future dilution, impacting existing investors' ownership percentages. The reverse stock split, ranging from 1-for-2 to 1-for-50, is a clear move to avoid delisting and attract institutional investors, but it doesn't change underlying company value. Competitors in the biotech space often face similar pressures, making these maneuvers common, but the magnitude here suggests substantial financial challenges or ambitious growth plans requiring significant capital infusion.

Risk Assessment

Risk Level: high — The proposal to increase authorized shares by 900% (from 100,000,000 to 1,000,000,000) and implement a reverse stock split up to 1-for-50 indicates significant potential for future shareholder dilution and a likely attempt to meet exchange listing requirements. These actions often precede further capital raises that can depress stock value and signal underlying financial distress.

Analyst Insight

Investors should carefully evaluate the potential for significant dilution and the implications of a reverse stock split on their holdings. Consider reducing exposure or hedging if you believe the company's fundamentals do not justify these aggressive capital structure changes.

Key Numbers

• 100,000,000 shares — Current authorized common stock (Proposed to increase to 1,000,000,000 shares)
• 1,000,000,000 shares — Proposed authorized common stock (A 900% increase from current levels)
• 1-for-2 — Minimum reverse stock split ratio (Board discretion for reverse stock split)
• 1-for-50 — Maximum reverse stock split ratio (Board discretion for reverse stock split)
• September 2, 2025 — Date of Special Meeting (Stockholders to vote on proposals)
• August 7, 2025 — Record Date (Eligibility to vote at Special Meeting)
• 50,349,149 shares — Common stock outstanding on Record Date (Entitled to vote at Special Meeting)
• $0.0001 — Par value per share (Common stock par value)

Key Players & Entities

• Processa Pharmaceuticals, Inc. (company) — Registrant seeking proxy approval
• George Ng (person) — Chief Executive Officer and designated proxy
• Wendy Guy (person) — Chief Administrative Officer and designated proxy
• SEC (regulator) — Securities and Exchange Commission
• Board of Directors (person) — Unanimously recommending proposals
• Delaware General Corporation Law (regulator) — Governing corporate actions

FAQ

Risk Factors

• Dilution from Authorized Share Increase [high — financial]: The proposal to increase authorized common stock from 100,000,000 to 1,000,000,000 shares (a 900% increase) creates significant potential for future dilution. While intended to provide flexibility for capital raises and strategic transactions, this expansion could substantially decrease the ownership percentage of existing shareholders if new shares are issued at unfavorable prices.
• Negative Market Perception of Reverse Stock Split [medium — market]: A reverse stock split, ranging from 1-for-2 to 1-for-50, is proposed to boost the stock price and potentially maintain listing compliance. However, reverse splits are often perceived negatively by the market, signaling underlying financial distress or an inability to achieve organic price appreciation, which could lead to further stock price declines.
• Dependence on Future Capital Raises [high — financial]: The significant increase in authorized shares is explicitly to provide flexibility for future capital raises. This suggests the company's current financial position may require substantial external funding to support its operations and development pipeline, posing a risk if such capital cannot be secured on favorable terms.
• Risk of Delisting [high — regulatory]: The reverse stock split is partly intended to maintain listing compliance. If the stock price does not meet exchange requirements, the company faces the risk of delisting, which would severely impact liquidity and investor confidence.
• Impact of Incentive Plan Share Increase [medium — financial]: Amending the 2019 Omnibus Incentive Plan to increase available shares, contingent on the authorized share increase, could lead to further dilution. Issuing new equity to employees and executives, especially at potentially low stock prices, can dilute existing shareholders' value.

Industry Context

Processa Pharmaceuticals operates in the highly competitive and capital-intensive biotechnology sector. Companies in this industry often face significant challenges in drug development, clinical trials, and regulatory approvals. Success typically requires substantial funding for research and development, making capital raises and strategic financial management critical for survival and growth. The industry is characterized by innovation, long development cycles, and high failure rates, with a constant need to secure financing to advance pipelines.

Regulatory Implications

The proposed reverse stock split is partly driven by the need to maintain compliance with stock exchange listing requirements, such as minimum share price thresholds. Failure to meet these requirements could lead to delisting, significantly impacting the company's liquidity and investor base. The increase in authorized shares, while providing financial flexibility, also brings scrutiny regarding potential dilution and its impact on shareholder value.

What Investors Should Do

1. Review the proposals carefully, especially the significant increase in authorized shares and the potential reverse stock split.
2. Vote on the proposals by the deadline to ensure your voice is heard.
3. Consider the long-term implications of increased authorized shares on your ownership percentage.

Key Dates

• 2025-09-02: Special Meeting of Stockholders — Stockholders will vote on critical proposals including increasing authorized shares, implementing a reverse stock split, and amending the incentive plan.
• 2025-08-07: Record Date — Establishes eligibility for stockholders to vote at the Special Meeting. 50,349,149 shares of common stock were outstanding on this date.
• 2025-08-13: Proxy Materials First Sent/Delivered — Commencement of the proxy solicitation period, providing stockholders with information to make voting decisions.
• 2026-12-31: Latest Effective Date for Reverse Stock Split — Provides a deadline for the Board of Directors to implement the reverse stock split, if approved.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information to shareholders about matters to be voted on at a special meeting. (This document outlines the proposals Processa Pharmaceuticals, Inc. is asking shareholders to approve, including share authorization changes and a reverse stock split.)

Authorized Shares

The maximum number of shares of stock that a corporation is legally permitted to issue, as specified in its charter. (Processa is seeking to increase its authorized shares from 100,000,000 to 1,000,000,000, which is a key proposal for future financing flexibility.)

Reverse Stock Split

A corporate action in which a company reduces the total number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (Processa proposes a reverse stock split (1-for-2 to 1-for-50) to potentially increase its stock price and meet listing requirements.)

Omnibus Incentive Plan

A type of employee stock option plan that allows a company to grant various types of equity-based compensation, such as stock options, stock awards, and stock appreciation rights. (The company seeks to amend its 2019 Omnibus Incentive Plan to increase the number of shares available for issuance, subject to the authorized share increase.)

Par Value

A nominal value assigned to a share of stock by the company's charter, often a very small amount like $0.0001. (The common stock of Processa has a par value of $0.0001 per share, which is relevant for accounting and legal purposes but not indicative of market value.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive notice of and vote at a shareholder meeting. (August 7, 2025, is the record date for Processa's special meeting, meaning only shareholders of record on this date can vote.)

Proxy

A document or electronic submission that authorizes another person to act on behalf of a shareholder, typically to vote their shares at a meeting. (The company is soliciting proxies from shareholders to ensure sufficient votes for the proposed measures at the Special Meeting.)

Year-Over-Year Comparison

This filing is a proxy statement for a special meeting, not an annual report, and therefore does not contain comparative financial data for the previous year. The primary focus is on upcoming shareholder votes for corporate actions, including a significant increase in authorized shares from 100,000,000 to 1,000,000,000 and a reverse stock split. New risks related to potential dilution and market perception of these actions are highlighted.

Key Financial Figures

• $0.0001 — mpany’s outstanding common stock, $0.0001 par value per share, at a ratio of not

Filing Documents

• formdef14a.htm (DEF 14A) — 477KB
• logo_001.jpg (GRAPHIC) — 12KB
• proxy_001.jpg (GRAPHIC) — 487KB
• proxy_002.jpg (GRAPHIC) — 370KB
• 0001493152-25-011883.txt ( ) — 1677KB

From the Filing

DEF 14A 1 formdef14a.htm DEF 14A UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Materials Pursuant to §240.14a-12 Processa Pharmaceuticals, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Rules 14a-6(i)(1) and 0-11. 601 21st Street, Suite 300 Vero Beach, FL, 32960 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON SEPTEMBER 2, 2025 NOTICE HEREBY IS GIVEN that a Special Meeting of Stockholders of Processa Pharmaceuticals, Inc. will be held at 601 21st Street, Suite 300, Vero Beach, FL, 32960, on September 2, 2025, beginning at 1:00 pm, Eastern Time for the following purposes: 1. To approve an amendment to our Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 1,000,000,000 shares (the “Charter Proposal”); 2. To approve an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, or the Certificate of Incorporation, to effect a reverse stock split of the Company’s outstanding common stock, $0.0001 par value per share, at a ratio of not less than 1-for-2 and not more than 1-for-50, such ratio to be determined in the sole discretion of the Company’s Board of Directors, without a corresponding reduction in the Company’s authorized shares, and to be effective upon a date determined by the Board of Directors no later than December 31, 2026 (the “Reverse Stock Split Proposal”); 3. To approve an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase the number of shares available for issuance under the Plan (the “OIP Proposal”), subject to the prior approval of the Charter Proposal; and 4 . To approve adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes in favor of the Charter Proposal, the Reverse Stock Split Proposal and/or the OIP Proposal or to establish a quorum (the “Adjournment Proposal”) . The Board of Directors (the “Board”) is not aware of any other business that will be presented for consideration at the Special Meeting. If any other matters should be properly presented at the Special Meeting or any adjournments or postponements of the Special Meeting for action by stockholders, the persons named in the form of proxy will vote the proxy in accordance with their best judgment on that matter. The Board of Directors unanimously recommends a vote “For” the Charter Proposal, the Reverse Stock Split Proposal, the OIP Proposal and the Adjournment Proposal. Information relating to the above Proposals is set forth in the attached Proxy Statement. Only stockholders of record at the close of business on August 7, 2025 (the “Record Date”) are entitled to receive notice of and to vote at the Special Meeting and any adjournments thereof. We hope you will be able to attend the meeting, but in any event, we would appreciate your submitting your proxy as promptly as possible. You may vote by Internet as instructed in the Notice of Internet Availability of Proxy Materials and in the accompanying proxy. If you received a copy of the proxy card by mail, you may also submit your vote by mail. We encourage you to vote by Internet. These methods are convenient and save the Company significant postage and processing charges. If you attend the meeting, you may revoke your proxy and vote in person. By order of the Board of Directors /s/ George Ng Chief Executive Officer Vero Beach, Florida August 13, 2025 601 21st Street, Suite 300 Vero Beach, FL, 32960 PROXY Special Meeting of Stockholders to be held on September 2, 2025 This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board”) of Processa Pharmaceuticals, Inc., a Delaware corporation (“Processa,” the “Company,” “we,” “our” or “us”), for use at the Special Meeting of Stockholders (the “Special Meeting”) to be held at 601 21st Street, Suite 300, Vero Beach, FL, 32960 on September 2, 2025, beginning at 1:00 p.m., Eastern Time, and at any postponements or adjournments there

View Full Filing

View this DEF 14A filing on SEC EDGAR